Brief: Lyell Immunopharma-Glaxosmithkline Informed Co As Part Of Strategic Actions, It Is Discontinuing Development Of Product Candidates Targeting Ny-Eso-1

Lyell Immunopharma

24/10/2022 23:12

Oct 24 (Reuters) - Lyell Immunopharma Inc  LYEL.O :
    * LYELL IMMUNOPHARMA-GLAXOSMITHKLINE INFORMED CO AS PART OF
STRATEGIC ACTIONS, IT IS DISCONTINUING DEVELOPMENT OF PRODUCT
CANDIDATES TARGETING NY-ESO-1
    * LYELL IMMUNOPHARMA INC - TERMINATION OF GSK AGREEMENT HAS
MINIMAL IMPACT TO LYELL OPERATIONS
    * LYELL IMMUNOPHARMA - TERMINATION IS EFFECTIVE ON DECEMBER
24,
2022
    * LYELL IMMUNOPHARMA - GSK PROVIDED NOTICE OF DECISION TO
TERMINATE THE LICENSE AND COLLABORATION AGREEMENT BETWEEN CO AND
GSK
    * LYELL-TERMINATION OF GSK AGREEMENT DO NOT CHANGE CO’S
GUIDANCE
THAT CASH TO BE SUFFICIENT TO MEET WORKING CAPITAL,CAPITAL
EXPENDITURE NEEDS INTO 2025

Further company coverage:  LYEL.O 
 ((Reuters.Briefs@thomsonreuters.com;))